The University of Sheffield spinout raised the capital from an international syndicate led by Northern Gritstone to scale its continuous-flow assembly process.
"This investment allows us to expand our team and demonstrate our unique technology on a commercial coating system, enabling partnership and evaluation by display manufacturing partners. We are proud to have a fantastic international consortium of complementary investors led by Northern Gritstone supporting our international ambitions to enable huge new market opportunities for microLED"
SCVC led the pre-seed round with backing from Deep Science Ventures and Cambridge Enterprise VC to help the startup expand its team and partnerships.
"Cellular machinery still rejects these therapies, limiting long-term effectiveness and forcing costly, unsafe doses. Our platform introduces a vital shift from trial-and-error screening to repeatable, engineering-driven DNA design,"
Serendipity Capital led the round with participation from NSSIF and SCVC.
"We’re thrilled by the strong investor support at this early stage. This raise is more than capital; it’s a vote of confidence in our mission to make quantum sensing operational. We’re building the tools to see what others can’t, in places that matter most, from hidden sinkholes to critical infrastructure. With this funding, we’re accelerating our roadmap to deliver smaller and more nimble field-ready systems."
The financing will be used to expand technical teams and accelerate the commercialisation of its proteomics platform.
"Portal Biotech’s technology offers unprecedented capabilities in protein identification and characterisation, providing unmatched detail on protein structure and modifications at the single-molecule level on accessible desktop instruments that bring this state-of-the-art characterisation to any lab. These powerful advances are essential for accelerating drug discovery and enhancing diagnostic precision, positioning Portal Biotech as the frontrunner in the race to unlock the full potential of protein sequencing."